


**Product Name** : RRX-001  
**Cat. No.** : PC-35927  
**CAS No.** : 925206-65-1  
**Molecular Formula** : C<sub>5</sub>H<sub>6</sub>BrN<sub>3</sub>O<sub>5</sub>  
**Molecular Weight** : 268.023  
**Target** : Immune Checkpoints  
**Solubility** : 10 mM in DMSO



## Biological Activity

RRX-001 (RRX001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity, RRx-001 is a dual small molecule checkpoint inhibitor by downregulating **CD47** and **SIRP- $\alpha$** .

RRX-001 targets CD133 + /CD44 + cancer stem cells from colon cancer cell-lines, HT-29, Caco-2, and HCT116, and inhibits Wnt pathway signalling with downregulation of c-Myc.

RRX-001 inhibits HCT 116 and decreases levels of the DNA methyltransferases DNMT1 and DNMT3a in a time and dose-dependent manner.

RRX-001 (RRX001) is a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia.

## References

Reid T, et al. *Lancet Oncol.* 2015 Sep;16(9):1133-1142. doi: 10.1016/S1470-2045(15)00089-3.

Scicinski J, et al. *Redox Biol.* 2015 Aug;5:422. doi: 10.1016/j.redox.2015.09.035.

Kim MM, et al. *Transl Oncol.* 2016 Apr;9(2):108-113.

Oronsky B, et al. *Invest New Drugs.* 2016 Jun;34(3):371-7.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com